All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Updated NCCN Guidelines for HL, FL and MCL
The National Comprehensive Cancer Network (NCCN) has updated its guidelines for several lymphoma subtypes in light of the new 2016 WHO classifications for Mature B-Cell, T-Cell, and NK-Cell conditions, and due to the latest drug approvals and clinical data. Below are some of the key changes in the updated NCCN Guidelines for Hodgkin Lymphoma, and other B-cell Lymphomas. The current version for both of these guidelines are Version 3.2016 for Hodgkin Lymphoma and Version 1.2017 for B-cell Lymphomas. Please see the individual guidelines for full details.
Hodgkin Lymphoma:
- Nivolumab is not indicated as a treatment option in relapsed or progressing classical HL after Autologous Hematopoietic Stem Cell Rescue (ASCR) with High Dose Therapy (HDT) and maintenance therapy with brentuximab vedotin
Follicular Lymphoma:
- Diagnosis Cyclin D1 (IHC) has been moved to ‘Useful under certain conditions’ from ‘Essential’
- Stage I and II have been separated into:
- Stage I (non-bulky), contiguous stage II (non-bulky) and the initial therapy is Involved Site Radiation Therapy (ISRT)
- Stage I (bulky), contiguous stage II (bulky) or non-contiguous stage II.
- First-line
- Addition of rituximab for consideration in patients with low tumor burden
- Lenalidomide and rituximab is now a category 2B recommendation, rather than category 3
- Second-line
- Idelalisib added in patients refractory to both alkylator and rituximab
- Added bendamustine + obinutuzumab to category 2A
MCL
- Less aggressive therapy
- Lenalidomide + rituximab treatment of MCL added to category 2A
- Second-Line therapy
- Venetoclax added to category 2A
- Rituximab, bendamustine, and bortezomib added to category 2B
- FCMR combination therapy was removed in MCL
- FMR combination therapy was removed in MCL
References
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?